ClinicalTrials.gg
CompletedNCT00112099Updated Sep 22, 2016

GCSSG-SPNX: Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: JCOG0110

A Phase 3 interventional study of Surgery: Splenectomy and Surgery: Spleen-preservation in Gastric Neoplasm, sponsored by Haruhiko Fukuda. Completed at 35 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-09-22.

Sponsored by Haruhiko Fukuda · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 181 studies in Stomach Neoplasms with a site in Japan — 33 open to participants now, 55 under way, 12 of them phase 3. Stomach Neoplasms · Japan.

Enrollment
43rd of 162
500 · median 158
Started
2002
with 4 others
Phase 3
54 of 181
4 open now
Registered
2nd of 181
by date

Among the 181 studies in Stomach Neoplasms with a site in Japan, this one is the 43rd largest by enrollment of the 162 interventional ones that give a count, is one of 5 that started in 2002, is one of 54 in phase 3, and was the 2nd registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

33 of the 181 studies in Stomach Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Stomach Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the role of splenectomy in potentially curative total gastrectomy for proximal gastric carcinoma in terms of survival benefit and post-operative morbidity.

Read the detailed description

European clinical trials of gastrectomy showed that splenectomy is an important risk factor for post-operative morbidity and mortality. Retrospective comparisons suggested that splenectomy is associated with poor long term survival. However, Japanese studies revealed that 20 - 30 % of patients with non-early carcinoma in the proximal stomach have nodal metastasis in the splenic hilum and therefore, pancreas-preserving splenectomy is part of the standard operation in specialized centers where splenectomy is not considered a risk factor for operative mortality. There have been no prospective randomized trials to evaluate the survival benefit of splenectomy in total gastrectomy for proximal gastric cancer.

Comparison: Total gastrectomy with pancreas-preserving splenectomy versus total gastrectomy without splenectomy

03

Conditions studied

  • Gastric Neoplasm

Browse trials for

Keywords

  • gastric neoplasm
  • gastrectomy
  • splenectomy
  • randomized trial
  • T2, T3 and T4 carcinoma in the proximal third of the stomach
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Preoperatively

  • proven adenocarcinoma
  • T2 or deeper lesion in the upper third of the stomach without involvement of the greater curvature or esophageal invasion, irrespective of the primary tumor location or existence of multiple foci
  • No distant , not linitis plastica ('Borrmann 4'), not stump carcinoma, no prior treatment for 364 Randomized trial for splenectomy gastric cancer
  • Sufficient organ function
  • Written .

Intra-operatively

  • T2/T3/T4 and N0/N1/N2, no tumor on the greater curvature, no direct invasion of the pancreas or spleen, negative peritoneal lavage cytology
  • No apparent nodal metastasis in the splenic hilum or along the splenic artery

Exclusion criteria

Exclusion Criteria:

  • Liver cirrhosis or portal hypertension
  • Idiopathic thrombocytopenic purpura
  • Severe pulmonary dysfunction
  • Synchronous or metachronous (within 5 years) .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (actual)

Study arms

  • Active comparator
    1

    Procedure/Surgery: Surgery: Splenectomy

    Procedure: Surgery: Splenectomy

  • Experimental
    2

    Procedure/Surgery: Surgery: Spleen-preservation

    Procedure: Surgery: Spleen-preservation

Interventions

  • ProcedureSurgery: Splenectomy

    Procedure/Surgery: Surgery: Splenectomy

  • ProcedureSurgery: Spleen-preservation

    Procedure/Surgery: Surgery: Spleen-preservation

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time frame: During the study conduct

Secondary outcomes

  1. Post-operative morbidity

    Time frame: 5 years

  2. operation time

    Time frame: day of the operation

  3. perioperative blood loss

    Time frame: 3 days after operation

07

Study locations

35 sites
  • Aichi Cancer Center Hospital
    Nagoya,Chikusa-ku,Kanokoden,1-1, Aichi 464-8681, Japan
  • Fujita Health University
    Toyoake,Kutsukake-cho,Dengakugakubo,1-98, Aichi 470-1192, Japan
  • National Cancer Center Hospital East
    Kashiwa,Kashiwanoha,6-5-1, Chiba 277-8577, Japan
  • National Hospital Organization Shikoku Cancer Center
    Matsuyama,Horinouchi,13, Ehime 790-0007, Japan
  • Gifu Municipal Hospital
    Gifu,Kashima-cho,7-1, Gifu 500-8323, Japan
  • Hiroshima City Hospital
    Hiroshima,Naka-ku,Motomachi,7-33, Hiroshima 730-8518, Japan
  • Itami City Hospital
    Itami,Koyaike,1-100, Hyogo 664-8540, Japan
  • Iwate Medical University
    Morioka,Uchimaru,19-1, Iwate 020-8505, Japan
  • Kagoshima University,Faculty of Medicine
    Kagoshima,Sakuragaoka,8-35-1, Kagoshima 890-8520, Japan
  • Kanagawa Cancer Center
    Yokohama,Asahi-ku,Nakao,1-1-2, Kanagawa 241-0815, Japan
  • Kyoto Second Red Cross Hospital
    Kyoto,Kamigyo-ku,Kamanza-Marutamachi,355-5, Kyoto 602-8026, Japan
  • Miyagi Cancer Center
    Natori,Medeshima-Shiode,Nodayama,47-1, Miyagi 981-1293, Japan
  • National Hospital Organization, Sendai Medical Center
    Sendai,Miyagino-ku,Miyagino,2-8-8, Miyagi 983-8520, Japan
  • Nagaoka Chuo General Hospital
    Nagaoka,Kawasaki,2041, Niigata 940-8653, Japan
  • Niigata Cancer Center Hospital
    Niigata,Kawagishi-cho,2-15-3, Niigata 951-8566, Japan
  • Tsubame Rosai Hospital
    Tsubame,Sawatari,633, Niigata 959-1228, Japan
  • Oita University Fuculty of Medicine
    Oita1-1,Hasama-machi,Oogaoka, Oita 879-5593, Japan
  • Osaka National Hospital
    Osaka,Chuo-ku,Hoenzaka,2-1-14, Osaka 540-0006, Japan
  • Osaka Medical Center for Cancer and Cardiovascular Diseases
    Osaka,Higashinari-ku,Nakamichi,1-3-3, Osaka 537-8511, Japan
  • Kinki University School of Medicine
    Osaka-Sayama,Ohno-higashi,377-2, Osaka 589-8511, Japan
  • Sakai Municipal Hospital
    Sakai,Minamiyasuicho,1-1-1, Osaka 590-0064, Japan
  • Osaka Medical College
    Takatsuki,Daigakucho,2-7, Osaka 569-0801, Japan
  • Toyonaka Municipal Hospital
    Toyonaka,Shibaharacho,4-14-1, Osaka 560-0055, Japan
  • Saitama Cancer Center
    Kita-adachi,Ina,Komuro,818, Saitama 362-0806, Japan
  • National Defense Medical College
    Tokorozawa,Namiki,3-2, Saitama 359-8513, Japan
  • Shizuoka General Hospital
    Shizuoka,Aoi-ku,Kitaando,4-27-1, Sizuoka 420-8527, Japan
  • Tokyo Metropolitan Komagome Hospital
    Bunkyo-ku,Honkomagome,3-18-22, Tokyo 113-8677, Japan
  • Tokyo Medical and Dental University Hospital
    Bunkyo-ku,Yushima,1-5-45, Tokyo 113-8519, Japan
  • National Cancer Center Hospital
    Chuo-ku,Tsukiji,5-1-1, Tokyo 104-0045, Japan
  • Cancer Institute Hospital
    Koto-ku,Ariake,3-10-6, Tokyo 135-8550, Japan
  • International Medical Center of Japan
    Shinjuku-ku,Toyama,1-21-1, Tokyo 162-8655, Japan
  • Tokyo Metropolitan Bokutoh Hospital
    Sumida-ku,Koutoubashi,4-23-15, Tokyo 130-8575, Japan
  • Toyama Prefectural Central Hospital
    Toyama,Nishinagae,2-2-78, Toyama 930-8550, Japan
  • Wakayama Medical University, School of Medicine
    Wakayama,Kimiidera,811-1, Wakayama 641-8510, Japan
  • Yamagata Prefectural Central Hospital
    Yamagata,Aoyagi,1800, Yamagata 990-2292, Japan
08

References and documents

Publications

  • Sano T, Yamamoto S, Sasako M; Japan Clinical Oncology Group Study LCOG 0110-MF. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. Jpn J Clin Oncol. 2002 Sep;32(9):363-4. doi: 10.1093/jjco/hyf085. PubMed 12417603 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2005
First posted
May 30, 2005
Start
Jun 2002
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Last update
Sep 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00112099
Lead sponsor
Haruhiko Fukuda
Collaborators
Ministry of Health, Labour and Welfare, Japan
Responsible party
Haruhiko Fukuda (JCOG Data Center, Japan Clinical Oncology Group) — Sponsor-investigator
First posted
May 30, 2005
Start date
Jun 2002
Primary completion
Mar 2014
Completion
Mar 2014
Last update
Sep 22, 2016

Study contacts

Mitsuru Sasako, MD, PhD
study chair · Hyogo Medical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion